Compounded Semaglutide: How to Spot a Legitimate Pharmacy

A legitimate compounding pharmacy gives you four facts you can verify: the pharmacy’s registration, the salt form on the label, the concentration on the vial, and who follows up with you. Compounded semaglutide is not FDA-approved, and the U.S. Food and Drug Administration (FDA) states, "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."¹ A physician treats this lack of premarket review as the key safety fact. You should not assume that a compounded vial has the same evidence, formulation, or delivery system as an FDA-approved semaglutide product.

Pharmacy Compounding and What It Means for FDA Approval

Compounding means a pharmacy prepares a drug for a medical need instead of supplying a finished FDA-approved product from a manufacturer. The resulting medicine remains outside FDA approval through that process.¹

Compounding can serve a legitimate medical purpose. The FDA states that “a compounded drug might be appropriate if a patient's medical need cannot be met by an FDA-approved drug.”¹ Your prescriber should be able to explain the medical need and the gap left by the approved product.

That exception leaves the oversight standard unchanged. The FDA does not review compounded semaglutide for safety, effectiveness, or quality before it reaches you.¹ Your decision therefore depends on the prescriber, the pharmacy, the formulation, and the follow-up plan.

Choosing a compounded product to solve an access or affordability problem leaves the clinical questions open. Your medical history, current medications, labs, and follow-up plan still need physician review.

If you need a broader explanation of the medication itself, read the semaglutide weight-loss guide. Questions about affordability belong in the separate GLP-1 cost guide.

Safety Evidence for Compounded Semaglutide

The question “is compounded semaglutide safe?” has no universal yes-or-no answer. Compounded products can differ by pharmacy, active ingredient, concentration, and presentation. Each version reaches you without FDA premarket review.¹

Some compounded products may be safe. Your prescriber still has to assess the compounded vial, because the findings established for the approved product do not carry over to it. Your own assessment starts with the pharmacy and the label.

The same product-specific standard applies to effectiveness. If your prescriber cites a semaglutide trial, ask whether the trial studied the exact product you would receive. Published trials of standardized semaglutide formulations excluded compounded semaglutide.

A compounded drug may fit a medical need left unmet by an approved drug. Your prescriber should document that need and discuss the added uncertainty with you.

Semaglutide Sodium and Semaglutide Acetate

Semaglutide sodium and semaglutide acetate are salt forms that place semaglutide in a different chemical form. They are different from the active ingredient used in FDA-approved semaglutide products.¹

The FDA states that it “does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug.”¹ A label that includes the word semaglutide leaves that chemical difference unresolved.

Which chemical form is in the vial is one of the most useful questions you can put to a prescriber or pharmacy. If the answer is semaglutide sodium or semaglutide acetate, ask your prescriber to explain why that form was selected and what evidence supports its use.

A vague answer prevents you from comparing the prescription with the vial you receive. Ask the pharmacy to state the salt form in writing, then check it against the label before the first dose.

Concentration and Dose Checks on Every Vial

Different concentrations and presentations can increase the chance of a dosing error. A volume used with one compounded vial may represent a different amount of medication in another vial.

The FDA reports that it “received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products.”¹ Approved pens and compounded vials can also use different delivery systems.

You should not have to calculate the prescribed amount from a concentration on your own. Ask the prescriber and pharmacist to confirm that the written prescription, vial label, and administration instructions refer to the same product.

If any part of the instructions is unclear, contact the prescriber or dispensing pharmacy before using the medication. Do not rely on directions from a different vial, an online forum, or another person’s prescription.

Low-dose use creates a separate set of questions. The GLP-1 microdosing guide addresses that practice without treating a compounded concentration as interchangeable with an approved product.

Reading the FDA Adverse-Event Reports

FDA adverse-event reports identify possible safety problems. Without confirmed causation or total user counts, they do not prove that a drug caused each reported event or establish an adverse-event rate.

As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 reports associated with compounded tirzepatide.¹ These reports record events associated with the products without confirming that the products caused them.

The reporting system also has an important limitation. According to the FDA, “federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported.”¹

The reported counts and the underreporting caveat need to be read together because a raw count alone cannot determine the safety of a compounded product for you. Your prescriber reads those reports alongside your history and the pharmacy’s registration to reach a decision about your vial.

Wegovy and Compounded Semaglutide Under Different Standards

Wegovy and compounded semaglutide are evaluated under different regulatory standards. FDA approval applies to a defined product, while compounded versions reach you without FDA premarket review for safety, effectiveness, or quality.¹

Question	Wegovy	Compounded Semaglutide
FDA approval	FDA-approved product	Not FDA approved
Premarket review	Reviewed by the FDA	Not reviewed by the FDA before marketing
Effectiveness evidence	Studied as a defined formulation	Effectiveness has not been established through FDA review
Active ingredient	Uses the approved active ingredient	May involve different forms, including semaglutide sodium or semaglutide acetate
Presentation	Standardized approved presentation	Concentration and presentation may vary

The STEP 1 trial studied 1,961 adults over 68 weeks. Mean body weight changed by minus 14.9% in the semaglutide group and minus 2.4% in the placebo group.² The trial tested no compounded product.

Those results establish evidence for the formulation and protocol studied. They do not establish that a compounded version is equally effective, chemically equivalent, or delivered with the same consistency. Where the approved product is available to you, it carries the evidence and the delivery system the trial actually tested.

Compounded Tirzepatide Under the Same Standard

Compounded tirzepatide carries the same premarket oversight issue described by the FDA. The FDA does not review compounded tirzepatide for safety, effectiveness, or quality before marketing.¹

The SURMOUNT-5 trial compared defined tirzepatide and semaglutide protocols in 751 participants. At week 72, mean weight change was minus 20.2% with tirzepatide and minus 13.7% with semaglutide.³ The trial excluded compounded tirzepatide and compounded semaglutide.

If a seller uses that trial to support a compounded product, ask how the dispensed formulation matches the product studied. The published result does not answer that question. Ask the seller for the formulation and concentration in writing, then let your prescriber compare them against the studied product.

Questions for Your Prescriber and Pharmacy

A legitimate prescription should come with clear answers about the pharmacy, vial, prescriber, and follow-up plan. Ask these questions before you fill the prescription:

• Who prepared the medication? Ask for the pharmacy’s full name and whether it is a state-licensed compounding pharmacy or a registered outsourcing facility.
• What is in the vial? Ask for the exact active ingredient, including whether the product uses semaglutide sodium, semaglutide acetate, or another form.
• What concentration was dispensed? Ask the pharmacist and prescriber to confirm how the vial concentration matches your written prescription. Do not perform the calculation yourself.
• Who is prescribing it? You should know the prescriber’s name and how to contact the clinical team.
• What medical information was reviewed? Ask whether the prescriber reviewed your symptoms, current medications, medical history, and relevant labs.
• What happens if you develop a side effect or receive unclear instructions? Ask who will respond, how quickly you can reach that person, and where adverse events are documented.

Clear paperwork matters. The prescription, pharmacy label, and clinical instructions should all describe the same medication.

Clinical Follow-Up Around a GLP-1 Prescription

Clinical supervision extends beyond writing a prescription. Your prescriber should review whether the treatment fits your medical history, current medications, symptoms, and laboratory results.

Follow-up also gives you a defined contact when side effects occur or the pharmacy changes the product presentation.

Men considering this category can find related clinical context in the GLP-1 guide for men.

The Opt Take on Compounded Semaglutide

At Opt Health, every lab we order is read by a physician before anyone is offered a treatment. When your treatment plan includes a prescription, it ships from our pharmacy to your home. The same physician reviews your current medications and existing conditions, then stays with you as the plan changes.

With compounded semaglutide, product identity, concentration, medical context, and follow-up each need a clear answer. A purchase decision cannot provide those answers. Your physician starts with a panel of more than 55 biomarkers spanning hormones, inflammation, cardiovascular risk, and more. The results are reviewed with your medical history and medication list.

Labs and a physician consultation repeat every three to four months. Your plan is adjusted based on what the numbers did. You can reach the care team by chat in the Opt app seven days a week if instructions or side effects require clinical attention. Membership is required for treatment because it makes continuity of care possible.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.